Screener
Kailera Therapeutics KLRA Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Kailera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Kailera Therapeutics’s 10-Q, filed May 26, 2026.
- Filed
- May 26, 2026, 4:29 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-239417
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from investing activities: | ||
| Purchases of marketable securities | (48,448) | (54,440) |
| Maturities of marketable securities | 71,297 | - |
| Net cash provided by (used in) investing activities | 22,849 | (54,440) |
| Cash flows from financing activities: | ||
| Proceeds from the exercise of stock options | 57 | - |
| Payments of deferred offering costs related to initial public offering | (3,037) | - |
| Net cash used in financing activities | (2,980) | - |
Item 1. Financial Statements.
FAQ
- What is Kailera Therapeutics's investing cash flow?
- Kailera Therapeutics (KLRA) reported investing cash flow of $22.85M in Q1 2026.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Kailera Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude